Details of Disease

General Information of Disease (ID: DISL8XZI)

Disease Name	Peptic ulcer
Synonyms	peptic ulcer; acute peptic ulcer without hemorrhage and without perforation; acute peptic ulcer without haemorrhage and without perforation; acute peptic ulcer with hemorrhage and perforation; acute peptic ulcer with hemorrhage; acute peptic ulcer with haemorrhage and perforation; acute peptic ulcer with haemorrhage
Disease Class	DA61: Peptic ulcer
Definition	A digestive system disease characterized by discontinuation in the inner lining of the gastrointestinal (GI) tract because of gastric acid secretion or pepsin.
Disease Hierarchy	DIS7JDYJ: Gastrointestinal disease DISHF2X6: Ulcer DISL8XZI: Peptic ulcer
ICD Code	ICD-11 ICD-11: DA61 Expand ICD-11 'DA61 Expand ICD-10 'K27; 'K27.0; 'K27.1; 'K27.2; 'K27.3; 'K27.4; 'K27.5; 'K27.6; 'K27.7; 'K27.9 Expand ICD-9 5.32E+11
Disease Identifiers	MONDO ID MONDO_0004247 MESH ID D010437 UMLS CUI C0030920 MedGen ID 45384 HPO ID HP:0004398 SNOMED CT ID 13200003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 24 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anisotropine Methylbromide	DMIJRF0	Approved	Small molecular drug	[1]
Cetraxate	DMSP4JX	Approved	Small molecular drug	[2]
Chlordiazepoxide	DMTN5XI	Approved	Small molecular drug	[3]
Dexlansoprazole	DM1DBV5	Approved	Small molecular drug	[4]
Diphemanil Methylsulfate	DMXVU6D	Approved	Small molecular drug	[5]
Esomeprazole	DM7BN0X	Approved	Small molecular drug	[6]
Famotidine	DMRL3AB	Approved	Small molecular drug	[7]
Homatropine Methylbromide	DMGBPSH	Approved	Small molecular drug	[8]
Hyoscyamine	DM804UR	Approved	Small molecular drug	[9]
Lansoprazole	DMXYLQ3	Approved	NA	[10]
Mepenzolate	DM8YU2F	Approved	Small molecular drug	[11]
Methantheline	DM8X4A1	Approved	Small molecular drug	[2]
Methylscopolamine	DM5VWOB	Approved	Small molecular drug	[12]
Nizatidine	DMGFV3Z	Approved	Small molecular drug	[13]
Omeprazole	DM471KJ	Approved	Small molecular drug	[14]
Oxyphencyclimine	DM3TABW	Approved	Small molecular drug	[15]
Pantoprazole	DMSVOCZ	Approved	Small molecular drug	[16]
Pirenzepine	DMP6M1N	Approved	Small molecular drug	[17]
Polaprezinc	DM1OC6A	Approved	Small molecular drug	[18]
Propantheline	DM2EN6G	Approved	Small molecular drug	[19]
Rabeprazole	DMMZXIW	Approved	Small molecular drug	[20]
Ranitidine	DM0GUSX	Approved	Small molecular drug	[21]
Scopolamine	DMOM8AL	Approved	Small molecular drug	[22]
Teprenone	DMZ44BT	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 24 Drug(s)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Axanum	DM80L2K	Phase 3	NA	[23]
Rebamipide	DM2GHCR	Phase 3	Small molecular drug	[24]
S-tenatoprazole	DMJ1DIB	Phase 2	NA	[25]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 8 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ecabapide	DMFOEVQ	Discontinued in Preregistration	Small molecular drug	[26]
SKF-96067	DMXW1Y3	Discontinued in Phase 3	Small molecular drug	[27]
KB-5492	DM7IP8U	Discontinued in Phase 2	Small molecular drug	[28]
SORAPRAZAN	DMCS8FM	Discontinued in Phase 2	Small molecular drug	[29]
TY-11345	DMQWA2R	Discontinued in Phase 2	Small molecular drug	[30]
SKF-97574	DM1XEUV	Discontinued in Phase 1	Small molecular drug	[31]
Saviprazole	DM79E6W	Terminated	Small molecular drug	[32]
SK&F-95601	DMRM7H0	Terminated	NA	[33]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SODIUM CITRATE	DMHPD2Y	Investigative	Small molecular drug	[34]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 13 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HRH2	TTQHJ1K	Limited	Biomarker	[36]
EDN1	TTJR60Z	moderate	Therapeutic	[37]
CNR1	TT6OEDT	Strong	Biomarker	[38]
CYP2C19	TTZ58XG	Strong	Genetic Variation	[39]
CYP2C9	TTR40YJ	Strong	Genetic Variation	[40]
GAST	TT4LRVO	Strong	Biomarker	[41]
GSR	TTEP6RV	Strong	Therapeutic	[42]
NOD1	TTYSRXM	Strong	Genetic Variation	[43]
SCT	TTOBVIN	Strong	Biomarker	[44]
SLCO1B1	TTFGXEB	Strong	Genetic Variation	[45]
ASAP3	TTB4ZEN	Definitive	Altered Expression	[46]
MGAM	TTXWASR	Definitive	Altered Expression	[47]
PGC	TT7K6AD	Definitive	Genetic Variation	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 DTT(s)

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HPGD	DEHKSC6	moderate	Therapeutic	[49]
ABO	DESIA7R	Strong	Genetic Variation	[50]
CYP2C18	DEZMWRE	Definitive	Genetic Variation	[40]
CYP2C8	DES5XRU	Definitive	Genetic Variation	[40]
------------------------------------------------------------------------------------

This Disease Is Related to 8 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
A4GNT	OT8GOL3T	moderate	Biomarker	[51]
ALKBH1	OTADGU5D	Strong	Biomarker	[52]
DDX53	OTHK3EGZ	Strong	Genetic Variation	[53]
SERPINB2	OT72QLZB	Strong	Genetic Variation	[54]
CHST2	OTV11IZF	Definitive	Genetic Variation	[55]
GGTLC1	OTWJKUHQ	Definitive	Biomarker	[56]
LXN	OTZQ2M6Y	Definitive	Genetic Variation	[57]
PLAAT1	OTM3M6P4	Definitive	Genetic Variation	[58]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DOT(s)

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 013428.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Chlordiazepoxide FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7208).
5	Drug information of Diphemanil Methylsulfate, 2008. eduDrugs.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5488).
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7074).
8	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 086310.
9	Clinical significance of M1 receptor antagonists. Pharmacology. 1988;37 Suppl 1:54-63.
10	Lansoprazole FDA Label
11	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010679.
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 316).
13	Nizatidine FDA Label
14	Omeprazole FDA Label
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7256).
16	Pantoprazole FDA Label
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 328).
18	Toxicity of the novel anti-peptic ulcer agent polaprezinc in beagle dogs. Arzneimittelforschung. 1995 Jan;45(1):52-60.
19	Propantheline FDA Label
20	Rabeprazole FDA Label
21	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1234).
22	Scopolamine FDA Label
23	ClinicalTrials.gov (NCT01994720) [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]. U.S. National Institutes of Health.
24	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 871).
25	ClinicalTrials.gov (NCT00282555) Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis. U.S. National Institutes of Health.
26	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000582)
27	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001218)
28	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001141)
29	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015211)
30	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001313)
31	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001921)
32	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000579)
33	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000578)
34	SODIUM CITRATE FDA Label
35	An overview of proton pump inhibitors. Gastroenterol Nurs. 2003 Sep-Oct;26(5):182-90.
36	Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.Pharmacol Ther. 2003 Apr;98(1):109-27. doi: 10.1016/s0163-7258(03)00015-9.
37	Endothelin-1, an ulcer inducer, promotes gastric ulcer healing via mobilizing gastric myofibroblasts and stimulates production of stroma-derived factors.Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G1041-50. doi: 10.1152/ajpgi.00462.2005. Epub 2005 Dec 29.
38	Involvement of nitric oxide in the gastroprotective effect of ACEA, a selective cannabinoid CB1 receptor agonist, on aspirin-induced gastric ulceration.Pharmazie. 2009 Sep;64(9):595-7.
39	CYP2C19*2 polymorphism in Polish peptic ulcer patients.Pharmacol Rep. 2019 Apr;71(2):272-275. doi: 10.1016/j.pharep.2018.12.011. Epub 2018 Dec 22.
40	CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.Clin Pharmacol Ther. 2013 Feb;93(2):195-203. doi: 10.1038/clpt.2012.215. Epub 2012 Oct 26.
41	Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.World J Surg Oncol. 2019 Dec 9;17(1):213. doi: 10.1186/s12957-019-1758-6.
42	The effect of a minor constituent of essential oil from Citrus aurantium: the role of -myrcene in preventing peptic ulcer disease.Chem Biol Interact. 2014 Apr 5;212:11-9. doi: 10.1016/j.cbi.2014.01.009. Epub 2014 Jan 27.
43	Nucleotide oligomerization domain 1 enhances IFN- signaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity.J Immunol. 2013 Apr 1;190(7):3706-15. doi: 10.4049/jimmunol.1200591. Epub 2013 Mar 4.
44	Peptic ulceration may be a hormonal deficiency disease.Med Hypotheses. 2008;70(6):1103-7. doi: 10.1016/j.mehy.2007.12.011. Epub 2008 Feb 15.
45	Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism.Curr Pharm Des. 2015;21(35):5066-72. doi: 10.2174/1381612821666150915105537.
46	ASAP3 regulates microvilli structure in parietal cells and presents intervention target for gastric acidity.Signal Transduct Target Ther. 2017 Feb 24;2:17003. doi: 10.1038/sigtrans.2017.3. eCollection 2017.
47	5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of -glucosidase and urease enzymes.Bioorg Chem. 2017 Jun;72:21-31. doi: 10.1016/j.bioorg.2017.03.007. Epub 2017 Mar 20.
48	Association between genetic polymorphism of the pepsinogen C gene and gastric body ulcer: the genetic predisposition is not associated with Helicobacter pylori infection.Gut. 1997 Oct;41(4):469-74. doi: 10.1136/gut.41.4.469.
49	15-PGDH inhibitors: the antiulcer effects of carbenoxolone, pioglitazone and verapamil in indomethacin induced peptic ulcer rats.Eur Rev Med Pharmacol Sci. 2013;17(15):2000-9.
50	Gastroduodenal Ulcers and ABO Blood Group: the Japan Nurses' Health Study (JNHS).J Epidemiol. 2018 Jan 5;28(1):34-40. doi: 10.2188/jea.JE20160204. Epub 2017 Oct 28.
51	Usefulness of the real-time reverse transcription-polymerase chain reaction assay targeted to alpha1,4-N-acetylglucosaminyltransferase for the detection of gastric cancer.Lab Invest. 2003 Feb;83(2):187-97. doi: 10.1097/01.lab.0000057001.21187.a0.
52	Interrelation between ABH blood group 0, Lewis(B) blood group antigen, Helicobacter pylori infection, and occurrence of peptic ulcer.Z Gastroenterol. 2002 May;40(5):273-6. doi: 10.1055/s-2002-30115.
53	Association between Helicobacter pylori genotypes and gastric disorders in relation to the cag pathogenicity island.Diagn Microbiol Infect Dis. 2007 Sep;59(1):7-16. doi: 10.1016/j.diagmicrobio.2007.03.019. Epub 2007 May 22.
54	Bacterial Energetic Requirements for Helicobacter pylori Cag Type IV Secretion System-Dependent Alterations in Gastric Epithelial Cells.Infect Immun. 2020 Jan 22;88(2):e00790-19. doi: 10.1128/IAI.00790-19. Print 2020 Jan 22.
55	Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding.J Gastroenterol Hepatol. 2014 Dec;29 Suppl 4:47-52. doi: 10.1111/jgh.12770.
56	Helicobacter pylori gamma-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease.Gastroenterology. 2010 Aug;139(2):564-73. doi: 10.1053/j.gastro.2010.03.050. Epub 2010 Mar 27.
57	Comorbidities and risk of mortality among hospitalized patients with idiopathic pulmonary fibrosis in Spain from 2002 to 2014.Respir Med. 2018 May;138:137-143. doi: 10.1016/j.rmed.2018.04.005. Epub 2018 Apr 11.
58	High relative content of lysophospholipids of Helicobacter pylori mediates increased risk for ulcer disease.FEMS Immunol Med Microbiol. 2005 Apr 1;44(1):17-23. doi: 10.1016/j.femsim.2004.10.003.